Search | Clinical Trials Finder

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Crohn Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis
Interventions: Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool, Standard Crohn's Disease Education; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, Social Anxiety Disorder
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Contraception
Interventions: Etonogestrel contraceptive implant; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: EDP-305, Oral Contraceptive; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Females
Interventions: PF-04965842, Ethinyl estradiol (EE) and levonorgestrel (LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatitis C Virus
Interventions: Ortho Tri-Cyclen®, BMS-650032; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 13 Years to 45 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Endometriosis, Unexplained Infertility
Interventions: Elagolix, Ortho Cyclen; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Endometriosis
Interventions: Elagolix, Placebo, Combined Oral Contraceptive; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 176
States / cities: Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more

Conditions: Healthy
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
Interventions: Estradiol or Placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Other Disorders of Bone Development and Growth
Interventions: Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR); Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Endometriosis, Pelvic Pain
Interventions: Oral Contraceptive, Depot-Leuprolide/Norethindrone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)
Interventions: transdermal 17β-E2 with cyclic progestin, oral 17β-E2 with cyclic progestin, transdermal EE+LNG; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 14 Years to 30 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Charlottesville, Virginia

Conditions: Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Interventions: Byetta 5Mcg Pen Injection; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cystic Fibrosis (CF)
Interventions: Loestrin (norethindrone acetate and ethinyl estradiol); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Ortho-Cyclen, AG200-15; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: JNJ-64155806 150 mg, Ethinylestradiol/drospirenone 0.02 mg/3 mg, COCP Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Oral Contraceptive
Interventions: Oral Contraceptive: Ortho-Novum® 1/35, Oral Contraceptive: Ovcon Fe®; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Postpartum Depressive Mood, Postpartum Sexual Function
Interventions: Ethinyl Estradiol 35mcg/Norethindrone 1mg, Ethinyl Estradiol 20mcg/Norethindrone 1mg; Drug
Lead sponsor: The Jones Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Menstrual Cycle, Healthy
Interventions: Not listed
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Metabolic Syndrome, Polycystic Ovary Syndrome
Interventions: wheat dextrin, Oral Contraceptives, Low-Dose, Maltodextrin; Dietary Supplement · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size, Oral Contraceptive
Interventions: Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Adherence to Oral Contraceptive Therapy
Interventions: Smartphone App Dosecast; Device
Lead sponsor: Belmont University; Other
Eligibility: 18 Years to 29 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 3
States / cities: Auburn, Alabama • Oxford, Mississippi • Nashville, Tennessee

Search by objective public record fields.

Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility

The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels

Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

Drug Interaction Oral Contraceptive Pill (OCP)

A Study to Look at Antiepileptic Drug Levels While on Lamictal or Depakote With or Without an Oral Contraceptive

Elagolix for Fertility Enhancement Clinical Trial

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.

Assessing the Impact of Contraceptives on Bone Health Using 41Ca

Medical Treatment of Endometriosis-Associated Pelvic Pain

Role of Estrogen on Skeletal Outcomes in FHA

Liver and Fat Regulation in Overweight Adolescent Girls

Gender Disparity and Hormones in Cystic Fibrosis

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

Oral Contraceptive (OC) Progestin Dose and Breast Proliferation

Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales

The Effects of Continuous Administration of a Monophasic Oral Contraceptive on Bleeding Days and Endometrial and Ovarian Function

Combined Oral Contraceptive Pill and Resistance Starch

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

Effect of a Smartphone Application on Oral Contraceptive Adherence in College Females